IRLAB’s Drug Candidate IRL757 Receives the Generic Name linepemat from the WHO
Gothenburg, Sweden, August 19, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company focused on discovering and developing new treatments for Parkinson’s disease, today announced that the World Health Organization (WHO) has assigned the company’s drug candidate IRL757 the unique generic name linepemat. The drug candidate is being developed as a potential first-in-class treatment for apathy associated with Parkinson’s disease and other neurological conditions and is currently being evaluated in the Phase Ib LIFT-PD study, which is fully funded by IRLAB’s collaborator, Otsuka Pharmaceutical (Otsuka).
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
CEO interview with Kristina Torfgård and CFO Gustaf Albèrt at Redeye
Redeye interviewed CEO Kristina Torfgård and CFO Gustaf Albèrt about IRLAB’s announced rights issue and the company’s priorities going forward. Published on June 16, 2026. Watch the video on Vimeo
Read More >